David B Ridley

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Price differentiation and transparency in the global pharmaceutical marketplace
    David B Ridley
    The Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Pharmacoeconomics 23:651-8. 2005
  2. ncbi request reprint Developing drugs for developing countries
    David B Ridley
    Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:313-24. 2006
  3. ncbi request reprint Spending on postapproval drug safety
    David B Ridley
    Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:429-36. 2006
  4. ncbi request reprint Impact of Medicaid preferred drug lists on therapeutic adherence
    David B Ridley
    Duke University, The Fuqua School of Business, Durham, North Carolina, USA
    Pharmacoeconomics 24:65-78. 2006
  5. doi request reprint Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases
    David B Ridley
    Fuqua School of Business, Duke University, Durham, NC 27708, USA
    Lancet 376:922-7. 2010
  6. ncbi request reprint Differential pricing of pharmaceuticals in the internet age
    David B Ridley
    Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, NC, USA
    J Ambul Care Manage 27:210-4. 2004
  7. ncbi request reprint Would greater transparency and uniformity of health care prices benefit poor patients?
    Margaret K Kyle
    Department of Strategic and International Management, London Business School, London, England, UK
    Health Aff (Millwood) 26:1384-91. 2007
  8. ncbi request reprint International price comparisons for novel and follow-on drugs
    David B Ridley
    Value Health 10:510-1; discussion 512-3. 2007

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Price differentiation and transparency in the global pharmaceutical marketplace
    David B Ridley
    The Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Pharmacoeconomics 23:651-8. 2005
    ..Furthermore, they should endeavour to keep low-priced and free drugs in the hands of the low-income consumers for which they were intended...
  2. ncbi request reprint Developing drugs for developing countries
    David B Ridley
    Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:313-24. 2006
    ..In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer...
  3. ncbi request reprint Spending on postapproval drug safety
    David B Ridley
    Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:429-36. 2006
    ..This study offers information for the debate on proposed changes to safety surveillance...
  4. ncbi request reprint Impact of Medicaid preferred drug lists on therapeutic adherence
    David B Ridley
    Duke University, The Fuqua School of Business, Durham, North Carolina, USA
    Pharmacoeconomics 24:65-78. 2006
    ..To estimate rates of non-adherence for statins following implementation of a preferred drug list (PDL)...
  5. doi request reprint Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases
    David B Ridley
    Fuqua School of Business, Duke University, Durham, NC 27708, USA
    Lancet 376:922-7. 2010
    ..Unlike the US system a European voucher would also accelerate pricing and reimbursement decisions. This scheme would be likely to provide substantial benefits to voucher holders, society, and public health organisations...
  6. ncbi request reprint Differential pricing of pharmaceuticals in the internet age
    David B Ridley
    Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, NC, USA
    J Ambul Care Manage 27:210-4. 2004
    ..We suggest strategic responses for manufacturers and policy makers...
  7. ncbi request reprint Would greater transparency and uniformity of health care prices benefit poor patients?
    Margaret K Kyle
    Department of Strategic and International Management, London Business School, London, England, UK
    Health Aff (Millwood) 26:1384-91. 2007
    ..We recommend alternative approaches to lowering prices for the poor and increasing efficiency...
  8. ncbi request reprint International price comparisons for novel and follow-on drugs
    David B Ridley
    Value Health 10:510-1; discussion 512-3. 2007